Articles

Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease
The authors assessed whether access to putative disease-modifying treatments results in a clinical benefit to patients with neurodegenerative diseases in randomized placebo-controlled trials. They concluded that active treatment is not beneficial and may be disadvantageous for patients with Alzheimer disease. Patients with neurodegenerative diseases are not harmed by assignment to placebo.
Page 18

From editorialists Rezak & de Carvalho: “Their results force us to consider the possibility that these unsubstantiated treatments may, in fact, add to the burden of patients’ disease and must be weighed in the context of avoiding harm in an already desperate situation.”
Page 12

REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment
In this study, REM sleep muscle activity (REM sleep without atonia [RSWA]) was quantitatively analyzed. Submentalis (chin) RSWA was substantially greater in patients with probable synucleinopathy than in those without synucleinopathy. Quantitative polysomnographic RSWA analysis is useful for distinguishing cognitive impairment phenotypes. Further confirmation is needed to clarify the diagnostic value of RSWA in dementia diagnosis.
Page 19

Anesthetic management during endovascular treatment of acute ischemic stroke in the MR CLEAN Registry
The authors compared outcomes of patients treated with 3 different anesthetic approaches during endovascular treatment. Local anesthesia resulted in the best functional outcome, with a more prominent advantage over conscious sedation than general anesthesia. Local anesthesia allows clinical assessment during the procedure, is less complex, and may reduce health care costs.
Page 26

Continued
Undetermined stroke genesis and hidden cardiomyopathies determined by cardiac magnetic resonance

Echocardiography may be insufficient to detect cardiomyopathies in patients with stroke. Cardiac MRI was performed in consecutive patients with ischemic stroke and showed a higher frequency of cardiomyopathies than reported in the general population. Cardiomyopathies should be considered a possible cause of stroke of undetermined etiology.

From editorialists de Freitas & Barreira: “The study by Fonseca et al. highlights that cardiomyopathies could contribute another, probably small, piece in the ESUS puzzle. Some of these pieces may require more sophisticated technology not currently routinely used in clinical practice for identification and characterization.”

Page 27

Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease (see p. 22)

1. Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease
2. What’s Trending: Gut Microbe to Brain Signaling: What Happens in Vagus...

In the first segment, Dr. Michelle Mauermann talks with Dr. Mary Reilly about her paper on targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease. In the second part of the podcast, Dr. David Lapides talks with Dr. Christine Fulling about gut microbiota and brain signaling via the vagus nerve to affect brain and behavior.

Disclosures can be found at Neurology.org.